Pharmaceutical company Merck & Co revealed Wednesday a significant collaboration with Google Cloud, committing up to $1 billion over multiple years to enhance artificial intelligence technology for drug development and medical research.
The announcement came during Google’s Cloud Next conference in Las Vegas, where executives outlined plans to integrate AI across Merck’s operations, from initial drug research through manufacturing and commercial activities.
“I easily see us investing a billion over the next several years in this, in those capabilities,” stated Dave Williams, Merck’s chief information and digital officer. “We’re not just buying tokens. It is really the tool set” that Google Cloud provides, including access to their Gemini Enterprise platform and engineering expertise.
Williams indicated the collaboration could extend for at least ten years, though no specific timeline has been established. Google Cloud engineers will work directly with Merck teams to implement AI solutions across various pharmaceutical processes.
The partnership focuses on using artificial intelligence to speed up medicine development, with both companies emphasizing potential benefits for patients worldwide.
“We’ve always said we wanted AI to play a positive role in society. One of the ways is to help people find cures to illnesses,” explained Thomas Kurian, CEO of Google Cloud. “They have the domain knowledge. We’re bringing the AI tools and platform and cyber capability to help them build using these tools.”
Merck plans to implement AI technology for computer-based laboratory simulations and faster regulatory approval processes. The company has already been using artificial intelligence for clinical study reports over the past two years with positive results.
“We feel there’s a tremendous opportunity there, and it’s a huge information challenge,” Williams noted about expanding AI applications in drug development.
The pharmaceutical company has already achieved significant efficiency gains using Google’s technology, reducing both time and costs by fifty percent when preparing regulatory dossiers needed for medicine reimbursement approvals in various countries.
“This isn’t a pilot,” Williams emphasized. “We’re submitting dossiers in markets using this new capability, and we’re now scaling it globally.”
Google Cloud operates as a division of Alphabet Inc., the parent company of Google.
